Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan Followed by Temozolomide for Subjects With Unresectable Hepatic Metastases From Ocular Melanoma

NCT00062933 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00062933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00062933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan Followed by Temozolomide for Subjects With Unresectable Hepatic Metastases From Ocular Melanoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2003
Completion date
March 31, 2008
Enrollment
40
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma